Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 301.8%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 195,700 shares, an increase of 301.8% from the October 15th total of 48,700 shares. Based on an average daily volume of 1,660,000 shares, the short-interest ratio is presently 0.1 days. Currently, 2.4% of the shares of the stock are sold short.

Windtree Therapeutics Price Performance

WINT opened at $0.53 on Thursday. Windtree Therapeutics has a 1-year low of $0.53 and a 1-year high of $22.36. The company has a market capitalization of $311,402.00, a price-to-earnings ratio of -0.02 and a beta of 0.64. The business has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $4.20.

Windtree Therapeutics (NASDAQ:WINT) last announced its earnings results on Monday, August 19th. The company reported ($20.91) earnings per share for the quarter, missing the consensus estimate of ($8.11) by ($12.80). Equities analysts expect that Windtree Therapeutics will post -2.38 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.